<span item_type="fundamental" item_id="018e16dfb3f8b2177188986b66d9f379" counter_id="ST/US/SNSE" env="prod"></span><span item_type="announcement" item_id="582668232634537857" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -3.62, beating the estimate of USD -4.11.</p><p></p><h3>Cash Position</h3><p>Cash, cash equivalents, and marketable securities were $25.0 million as of September 30, 2025, compared to $41.3 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585dex991.htm"></span></p><h3>Research and Development (R&amp;D) Expenses</h3><p>R&amp;D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024. The decrease was primarily due to lower personnel and facilities costs, and reduced lab supply costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585dex991.htm"></span></p><h3>General and Administrative (G&amp;A) Expenses</h3><p>G&amp;A expenses were $2.3 million for the quarter ended September 30, 2025, compared to $3.2 million for the quarter ended September 30, 2024. The decrease was mainly due to lower personnel costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585dex991.htm"></span></p><h3>Net Loss</h3><p>Net loss was $4.6 million for the quarter ended September 30, 2025, compared to $7.3 million for the quarter ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585dex991.htm"></span></p><h3>Total Assets and Liabilities</h3><p>Total assets were $27.6 million as of September 30, 2025, compared to $45.4 million as of December 31, 2024. Total liabilities were $4.6 million as of September 30, 2025, compared to $7.0 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585dex991.htm"></span></p><h3>Outlook / Guidance</h3><p>The company announced the discontinuation of solnerstotug development and is exploring strategic alternatives to maximize shareholder value, which may include asset sales, licensing, collaborations, or a sale of the company. A workforce reduction of approximately 65% has been implemented to preserve cash while retaining a small team to assist in exploring these strategic alternatives.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585dex991.htm"></span></p>

Sensei Biotherapeutics | 8-K: FY2025 Q3 Revenue: USD 0